LGK-974 is under clinical development by Novartis and currently in Phase I for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase I drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LGK-974’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LGK-974 is under development for the treatment of solid tumor, triple negative breast cancer (first and second), cervical squamous cell cancer, esophageal squamous cell cancer, lung squamous cell cancer, colorectal cancer, melanoma, metastatic triple negative breast cancer, metastatic pancreatic adenocarcinoma, metastatic head, and neck squamous cell cancer. The drug candidate is administered orally. It targets porcupine, a membrane-bound O-acyltransferase enzyme. It was also under development for gastric cancer, metastatic colorectal cancer.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of LGK-974’s drug-specific PTSR and LoA scores, buy the report here.